Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12003846 | 0.91 | THRB (0.49) | THRBKMT2AIKBKBACSS2LTB4R | |
| SCHEMBL12004395 | 0.79 | VDR (0.33) | THRBKMT2ALTB4R | |
| SCHEMBL12003989 | 0.79 | ALOX5 (0.35) | THRBKMT2ALTB4RPTGESALOX5 | |
| SCHEMBL12004151 | 0.77 | VDR (0.32) | — | |
| SCHEMBL12004064 | 0.76 | CYP1A2 (0.41) | KMT2ALMNA | |
| SCHEMBL12004130 | 0.76 | NUDT1 (0.42) | — | |
| SCHEMBL9934908 | 0.74 | IKBKB (0.31) | THRBKMT2AIKBKB | |
| SCHEMBL12003957 | 0.72 | TP53 (0.42) | ALDH1A1LMNA | |
| SCHEMBL22930422 | 0.69 | NUDT1 (0.60) | THRBKMT2AIKBKBALDH1A1LMNA | |
| SCHEMBL10767683 | 0.67 | KMT2A (0.53) | THRBKMT2AIKBKBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | THRB 272/4885KMT2A 3915/4885IKBKB 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.